
Quick Q&A: Benjamin N. Rome, M.D., M.P.H., on the IRA and drug launch prices
Drug launch prices are rising, but Benjamin N. Rome, M.D., M.P.H., and colleagues found no evidence manufacturers raised them in response to the Inflation Reduction Act.
Prescription drug launch prices have continued to rise, but researchers found no evidence that manufacturers have responded to the drug pricing provisions of the Inflation Reduction Act (IRA) by raising launch prices further as many predicted. Benjamin N. Rome, an assistant professor at Harvard Medical School and a researcher with the Program On Regulation, Therapeutics, And Law at Harvard-affiliated Brigham and Women's Hospital in Boston, co-authored
Rome explains that the IRA empowers Medicare to negotiate prices for a limited number of prescription drugs after they have been on the market for at least seven years. It also requires drug manufacturers to pay Medicare rebates when their prices rise faster than inflation, a policy that has been in place in Medicaid for many years. Because both policies lower prices later in a drug's life cycle, there was a lot of speculation that manufacturers would respond by starting with higher prices, giving themselves room to negotiate and avoiding the inflation penalties, Rome says.
But there was another side to that argument: If manufacturers could have set higher prices before the IRA, they would have done so already.
Rome said he understood the view that the IRA might but had his doubts. "I wasn't 100% sold that there was going to be such a stark increase," he said. Part of the reason was earlier research by Rome and his colleagues showing that launch prices were already increasing rapidly. That made it hard to tell whether prices were rising because of the IRA or simply continuing the prior trend.
In this video, Rome walks through the theory behind fears of higher launch prices under the IRA and why the existing upward trend made him skeptical from the start.
Related to this article








